Despite the improvement in therapy of ovarian cancer achieved by the introduction of platinum compounds since 1980, a major problem remains: the emergence of resistant tumour cell populations resulting in progressive ovarian cancer in the majority of patients presenting with advanced disease (Ozols, 1985) .
Paclitaxel, an antimicrotubule agent, has shown clear activity as salvage therapy in epithelial ovarian carcinoma. Most important, it demonstrates activity in tumours that have displayed resistance to platinum compounds, a situation in which other salvage therapies have very limited activity (Thigpen et al., 1994) . The role of paclitaxel combined with cisplatin in the initial treatment of advanced disease is currently being explored (McGuire et al., 1993) . With regard to the combination of paclitaxel and cisplatin it has become clear that the cytotoxic activity of the combination strongly depends on the sequence of administration (Rowinsky et al., 1991; Jekunen et al., 1994 
Cell lines and culture techniques
The human ovarian carcinoma cell line A2780 (WT for 'wild type') was established from a non-pretreated patient with ovarian carcinoma, and the cisplatin-resistant variant A2780 CP2 was obtained from R Ozols and T Hamilton (Fox Chase Cancer Center, Philadelphia, PA, USA) (Rogan et al., 1984) . A2780 CP2 cells are about 15-fold resistant to cisplatin (Masuda et al., 1988; Hamilton et al., 1985) . The human ovarian adenocarcinoma cell lines TR 170 and the cisplatinresistant subline TR 170/731 were obtained from BT Hill (Pierre Fabre Research Center, Paris, France). The cisplatinresistant line TR 170/731 was generated by intermittent exposure to cisplatin with a 10-fold resistance. The cell lines were maintained in RPMI1640 containing L-glutamine, 10% heat-inactivated fetal calf serum and 25% DMEM. All cell lines were kept in an atmosphere of 5% carbon dioxide in air at 37°C.
Cytotoxicity assay
The cytotoxicity of either paclitaxel, etoposide and hydroperoxy-ifosfamide was assessed by sulphorhodamin B assay (Skehan et al., 1990) . Cells in exponential growth were washed with phosphate-buffered saline (PBS), trypsinised with 0.25% trypsin/EDTA for 2 min at 37°C, counted and seeded as a single-cell suspension at a density of 1000 cells per well (A2780; A2780 CP2) or 5000 cells per well (TR 170; TR 170/731) respectively in 96-well microtitre plates (Falcon, Heidelberg, Germany). Cells were allowed to attach overnight.
were treated identically. After a total incubation time of 120 h, cells were fixed with 50 pl of 50% trichloroacetic acid (TCA) for at least 1 h at 4°C, washed three times with PBS and stained as originally described. Eight wells were used for each drug concentration and all experiments were performed in triplicate. The drug concentration that inhibited cell growth by 50% (IC50) was obtained from semilogarithmic dose -response plots.
The standard isobologram methodology (50% isodose) was used to determine the interaction of paclitaxel and hydroperoxy-ifosfamide or etoposide respectively. The schedule-dependent interactions of the drug combinations were classified as synergistic, additive or antagonistic as described by Berenbaum (1989) . In brief, dose -response curves should be determined for each agent alone, and with two agents in combination at a fixed ratio equivalent to the ratio of their IC50 values. The nature of the interaction between the drugs could then be assessed by median effect computer analysis of the dose -response curves in order to calculate the combination index at the level of 50% cell kill. Values of <1 indicate synergy, a value of 1 indicates additivity and values > 1 indicate antagonism. With the mathematical basis of the combination index by median effect analysis we are able to analyse the isobols graphically. Berenbaum determined an upward concavity as synergistic, a downward concavity as antagonistic (see Figure 1 ). Each point in the figure presented represents the mean of three separate experiments.
[3H]Paclitaxel uptake and retention Exponentially growing cells of the cell line A2780 CP2 were seeded in plastic flasks and incubated either with 50% of the IC50 for etoposide or drug-free medium. cells were centrifuged at 2000 U min-1, washed three times with ice-cold PBS and lysed with 1 N sodium hydroxide for 24 h. The lysates were collected and counted in a liquid scintillation counter. Results are expressed as pmol paclitaxel (total concentration) 10-6 cells. For the measurement of [3H]paclitaxel retention, the cells were centrifuged, washed with ice-cold PBS and resuspended in L-15 medium at 37°C. Samples were taken after 5, 10, 20, 30, 60 and 120 min and processed as described above. All experiments were performed in triplicate.
DNA flow cytometry
To assess the changes in the cell cycle distribution, flow cytometry analysis was performed 24 h, 48 h and 72 h after exposure to etoposide in the cisplatin-resistant ovarian cancer cell line A2780 CP2. Cells were incubated in a DNA staining solution containing propidium iodide (50 ig ml-') and RNAase (Type 111-A, bovine pancreas, 4 KU ml-1) and kept cold and dark for at least 30 min until flow cytometry analysis was carried out (Krishan, 1975 Figure 1 . The combinations of either paclitaxel-hydroperoxy-ifosfamide or paclitaxel -etoposide were found to be additive or synergistic when the drugs were given simultaneously or when paclitaxel was given 24 h before hydroperoxy-ifosfamide or etoposide respectively. However, when etoposide or hydroperoxy-ifosfamide were given before paclitaxel, antagonistic interactions were observed. A summary of the observed interactions is given in Table II. In order to assess the extent and the duration of the protection against paclitaxel cytotoxicity induced by pretreatment with etoposide, A2780 CP2 cells were exposed to a fixed concentration of etoposide (50% IC50) followed by paclitaxel for 2 h either 24 h, 48 h or 72 h later. The antagonism of the sequence etoposide followed by paclitaxel was time dependent. Pretreatment with etoposide significantly reduced the activity of paclitaxel for up to 24 h. However, no reduction of paclitaxel cytotoxicity was seen when the drugs were given 48 h or 72 h apart ( Figure 2) .
As etoposide is known to influence progression through the cell cycle and paclitaxel is a drug with preferential activity against cells in G2/M phase, we assessed the changes in cell cycle distribution after exposure to etoposide. The results are shown in Figure 3 . Compared with non-treated cells, a gradual increase in cells with S-phase and a corresponding decrease of cells with either G1 or G2/M DNA content was seen, indicating a temporal transition block at the S/G2 boundary. However, these changes in cell cycle distribution were discrete and do not offer a sufficient explanation for the marked antagonism between etoposide and paclitaxel.
To further explain the marked schedule-dependent antagonism between etoposide and paclitaxel, the effect of etoposide on the cellular accumulation and retention of 3H-labelled paclitaxel was measured. No significant differences in paclitaxel uptake could be detected between cells that were 0 0 100 50 Per cent IC50 Paclitaxel Figure 2 Cytotoxicity assay of the sequence etoposide followed by paclitaxel in the cisplatin-resistant cell line A2780 CP2. Cells were exposed to a fixed concentration of etoposide for 2h (50% IC50), washed and exposed to paclitaxel either 24h (0), 48h (A) or 72h (0) and non-pretreated cells (A).
pretreated with etoposide and the untreated cells. Furthermore the peak concentrations of paclitaxel at the end of a 2 h loading period were also not changed. However cells pretreated with etoposide retained significantly less drug when incubated in drug-free medium than in non-pretreated cells (Figure 4 ).
Discussion
Many groups, including our own, have demonstrated schedule-dependent interactions between paclitaxel and cisplatin in human ovarian and gastric cancer cell lines in vitro and in vivo (Vanhoefer et al., 1995; Jekunen et al., 1994) .
The present study demonstrates a marked scheduledependent antagonism between paclitaxel and hydroperoxyifosfamide and between paclitaxel and etoposide in cisplatinsensitive and cisplatin-refractory human ovarian carcinoma cell lines. This antagonism was seen for all sequences when either hydroperoxy-ifosfamide or etoposide were given before paclitaxel. In contrast, when cells were exposed to paclitaxel before either hydroperoxy-ifosfamide or etoposide or when a simultaneous application of paclitaxel with one or both drugs was performed additive or synergistic interactions were seen. However, unlike cisplatin for which we could demonstrate a reduction in the activity of paclitaxel up to 72 h after exposure to cisplatin, the antagonism between etoposide and paclitaxel could only be demonstrated for 24 h and cells regained full sensitivity to paclitaxel after 48 h.
As paclitaxel predominantly acts on cells in late G2/M phase, the cell cycle distributions after exposure to etoposide were assessed. More cells were observed to be in late S-phase and G2/M phase 24 h after exposure to etoposide than in the control samples, indicating that a block of the cell cycle traverse is most likely not responsible for the observed antagonism. The biochemical basis for these schedule-dependent interactions between paclitaxel and either cisplatin, etoposide or hydroperoxy-ifosfamide have not been fully elucidated. It has been demonstrated that pretreatment with cisplatin reduces the retention of paclitaxel inside the cell. This might be due to alterations of the tubulin binding site, which will result in reduced activity of paclitaxel. Additionally, it could be demonstrated that a profound depletion of cellular glutathione pools will also reduce the efficacy of paclitaxel in vitro (Vanhoefer et al., 1995) . Furthermore, clinical data have shown a reduced total body clearance of paclitaxel in patients who have been pretreated with cisplatin (Rowinsky et al., 1991) . Therefore a detailed investigation of the influence of drug scheduling on the cytotoxic efficacy of combinations containing paclitaxel might lead to a more rational design of clinical protocols.
In the present study etoposide had no effect on the cellular uptake of 3H-labelled paclitaxel. However, as also demonstrated for cisplatin a significantly increased retention of paclitaxel in non-pretreated cells was seen compared with cells that have been exposed to etoposide. Further studies will have to clarify whether the reduced cellular retention of paclitaxel is due to changes in the affinity of tubulin binding sites for paclitaxel, which could be one explanation for the schedule-dependent interactions.
These in vitro data suggest that clinical protocols using the sequence of either etoposide or ifosfamide followed by paclitaxel could have reduced therapeutic efficacy. We have started a phase I study with paclitaxel given on day 1 followed by ifosfamide given on days 2-5 in cisplatinpretreated ovarian cancer patients. We will include the reversed schedule in order to assess differences in side-effects and clinical outcome. In addition, further studies will have to clarify the exact biological and biochemical mechanisms that are responsible for the significant schedule-dependent interactions. 
